Pharmaceutical Executive June 29, 2020
Brand surges, new ranking battles, and M&A-sparked upswings highlight Pharm Exec’s annual listing of the top global biopharma players, but in the shadow of COVID-19, a peek behind the numbers also tells another story—one that reinforces the industry’s wider health mission
With much of the world’s attention today naturally focused on the COVID-19 global crisis—and for governments, the healthcare and medical communities, and others, fixed squarely on critical response, resource, and research efforts to end the pandemic—it may seem an odd juxtaposition to highlight our annual listing of the top 50 biopharma sales producers.Or could it be that this backdrop actually offers very real context or perspective to this year’s ledger, our 20th? Perhaps never more apparent than today is...
Today's Sponsors
Today's Sponsor